Alpha 2.0

» Articles » PMID: 36233539

Cardiac Biomarkers and Risk Scores in Relation with History of Atherosclerotic Cardiovascular Disease in Patients Admitted with COVID-19: The Experience of an Eastern European Center

Overview

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Oct 14

PMID 36233539

Authors

Authors

Catalina Lionte

Victorita Sorodoc

Raluca Ecaterina Haliga

Cristina Bologa

Alexandr Ceasovschih

Oana Sirbu

Victoria Gorciac

Andrei-Costin Chelariu

Alexandra Stoica

Roxana Elena Tocila

Minerva Codruta Badescu

Irina-Iuliana Costache

Christiana Brigitte Sandu

Elisabeta Jaba

Laurentiu Sorodoc

Affiliations

Affiliations

Soon will be listed here.

Abstract

Background: Data regarding the combined prognostic role of biomarkers and risk scores in relation with the history of atherosclerotic cardiovascular disease (ASCVD) in COVID-19 patients are lacking.

Methods: The aim of this observational cohort study was to evaluate the combined prognostic value of N-terminal pro B-type natriuretic peptide (NT-pro BNP), troponin and risk scores in relation with ASCVD history in hospitalized COVID-19 patients. The primary composite endpoint was Intensive Care Unit (ICU) admission and death.

Results: From April 2020 to June 2022, 1066 consecutive COVID-19 patients with available biomarkers upon admission were included. During a median follow-up period of 12 days, 176 patients (16.5%) died. Independent predictors of ICU admission and death in patients with ASCVD were NT-pro BNP (HR 2.63; 95% CI, 1.65-4.18) and troponin (HR 1.51; 95% CI, 1.13-2.03). In patients without ASCVD, only NT-pro BNP was predictive for the primary endpoint (HR 1.66; 95% CI, 1.10-2.53). This remained significant after adjustment for other relevant covariates (HR 3.54; 95% CI, 1.98-6.33) in patients with ASCVD and in patients without ASCVD (HR 1.82; 95% CI, 1.02-3.26).

Conclusions: These data showed the combined prognostic accuracy of NT-pro BNP and troponin in relation with ASCVD history for ICU admission and death in COVID-19 patients.

Citing Articles

The Significance of Low Magnesium Levels in COVID-19 Patients.

Coman A, Ceasovschih A, Petroaie A, Popa E, Lionte C, Bologa C Medicina (Kaunas). 2023; 59(2).

PMID: 36837480 PMC: 9965430. DOI: 10.3390/medicina59020279.

References

1.

Lippi G, Wong J, Henry B . Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020; 130(4):304-309. DOI: 10.20452/pamw.15272. View

2.

Thygesen K, Alpert J, Jaffe A, Chaitman B, Bax J, Morrow D . Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2018; 40(3):237-269. DOI: 10.1093/eurheartj/ehy462. View

3.

Khan S, Tasleem Rasool S, Ahmed S . Role of Cardiac Biomarkers in COVID-19: What Recent Investigations Tell Us?. Curr Probl Cardiol. 2021; 46(10):100842. PMC: 7977033. DOI: 10.1016/j.cpcardiol.2021.100842. View

4.

. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. Eur Heart J. 2021; 43(11):1033-1058. PMC: 8690026. DOI: 10.1093/eurheartj/ehab696. View

5.

Okor I, Bob-Manuel T, Price J, Sleem A, Amoran O, Kelly J . COVID-19 Myocarditis: An Emerging Clinical Conundrum. Curr Probl Cardiol. 2022; 47(9):101268. PMC: 9135640. DOI: 10.1016/j.cpcardiol.2022.101268. View

6.

Baker K, Hanrath A, van der Loeff I, Kay L, Back J, Duncan C . National Early Warning Score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. Clin Med (Lond). 2021; 21(2):84-89. PMC: 8002770. DOI: 10.7861/clinmed.2020-0688. View

7.

Shankar-Hari M, Vale C, Godolphin P, Fisher D, Higgins J, Spiga F . Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021; 326(6):499-518. PMC: 8261689. DOI: 10.1001/jama.2021.11330. View

8.

Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F . Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020; 41(22):2070-2079. PMC: 7239100. DOI: 10.1093/eurheartj/ehaa408. View

9.

Faxon D, Creager M, Smith Jr S, Pasternak R, Olin J, Bettmann M . Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2004; 109(21):2595-604. DOI: 10.1161/01.CIR.0000128517.52533.DB. View

10.

Muneer M, Akbar I . Acute Metabolic Emergencies in Diabetes: DKA, HHS and EDKA. Adv Exp Med Biol. 2020; 1307:85-114. DOI: 10.1007/5584_2020_545. View

11.

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

12.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

13.

Chehrazi M, Yavarpour H, Jalali F, Saravi M, Jafaripour I, Hedayati M . Optimal cut points of N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) in patients with COVID-19. Egypt Heart J. 2022; 74(1):16. PMC: 8924742. DOI: 10.1186/s43044-022-00253-1. View

14.

De Giorgi A, Fabbian F, Greco S, Di Simone E, De Giorgio R, Passaro A . Prediction of in-hospital mortality of patients with SARS-CoV-2 infection by comorbidity indexes: an Italian internal medicine single center study. Eur Rev Med Pharmacol Sci. 2020; 24(19):10258-10266. DOI: 10.26355/eurrev_202010_23250. View

15.

Stefanini G, Chiarito M, Ferrante G, Cannata F, Azzolini E, Viggiani G . Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020; 106(19):1512-1518. DOI: 10.1136/heartjnl-2020-317322. View

16.

Zwaenepoel B, Dhont S, Hoste E, Gevaert S, Schaubroeck H . The Prognostic Value of Cardiac Biomarkers and Echocardiography in Critical COVID-19. Front Cardiovasc Med. 2021; 8:752237. PMC: 8602560. DOI: 10.3389/fcvm.2021.752237. View

17.

Caro-Codon J, Rey J, Buno A, Iniesta A, Rosillo S, Castrejon-Castrejon S . Characterization of NT-proBNP in a large cohort of COVID-19 patients. Eur J Heart Fail. 2021; 23(3):456-464. PMC: 8013330. DOI: 10.1002/ejhf.2095. View

18.

. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637-1645. PMC: 8084355. DOI: 10.1016/S0140-6736(21)00676-0. View

19.

Shanbhag V, Arjun N, Chaudhuri S, Pandey A . Utility of Age-adjusted Charlson Comorbidity Index as a Predictor of Need for Invasive Mechanical Ventilation, Length of Hospital Stay, and Survival in COVID-19 Patients. Indian J Crit Care Med. 2021; 25(9):987-991. PMC: 8664016. DOI: 10.5005/jp-journals-10071-23946. View

20.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View